Prasugrel
- Generic Name
- Prasugrel
- Brand Names
- Effient, Efient, Prasugrel Viatris (previously Prasugrel Mylan)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H20FNO3S
- CAS Number
- 150322-43-3
- Unique Ingredient Identifier
- 34K66TBT99
- Background
Prasugrel, a thienopyridine derivative, is a platelet activation and aggregation inhibitor structurally and pharmacologically related to clopidogrel and ticlopidine. Similar to clopidogrel, prasugrel is a prodrug that requires enzymatic transformation in the liver to its active metabolite, R-138727. R-138727 irreversibly binds to P2Y12 type ADP receptors on ...
- Indication
用于心力衰竭、卒中、不稳定心绞痛等心脑血管疾病以及有急性冠状动脉综合征需要进行经皮冠脉介入术的患者。
- Associated Conditions
- Cardiovascular Events
- Associated Therapies
- -
Cangrelor to Clopidogrel or Prasugrel Transition Study
- Conditions
- Interventions
- First Posted Date
- 2013-11-08
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 15
- Registration Number
- NCT01979445
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2019-03-01
- Lead Sponsor
- LMU Klinikum
- Target Recruit Count
- 2600
- Registration Number
- NCT01959451
- Locations
- 🇦🇹
Wilhelminenspital Wien, 3. Medizinische Abteilung, Vienna, Austria
🇦🇹Medizin-Universität Graz, Univ. Klinik für Innere Medizin, Graz, Austria
🇭🇺Heart Center Szeged, Szeged, Hungary
Differential Effect of Ticagrelor Versus Prasugrel Maintenance Dose on Endothelial Function of Peripheral Vessels in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2013-10-08
- Last Posted Date
- 2017-01-10
- Lead Sponsor
- University of Patras
- Target Recruit Count
- 22
- Registration Number
- NCT01957540
- Locations
- 🇬🇷
Patras University Hospital, Patras, Achaia, Greece
Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome
- Conditions
- Interventions
- First Posted Date
- 2013-09-26
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Gyeongsang National University Hospital
- Target Recruit Count
- 255
- Registration Number
- NCT01951001
- Locations
- 🇰🇷
Gyeonsang National University Hospital, Jinju, Gyeonsangnam-do,, Korea, Republic of
Prospective, Randomized Trial of Ticagrelor Versus Prasugrel in Patients With Acute Coronary Syndrome
- First Posted Date
- 2013-09-18
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Deutsches Herzzentrum Muenchen
- Target Recruit Count
- 4018
- Registration Number
- NCT01944800
- Locations
- 🇩🇪
Universitäts-Herzzentrum Freiburg/ Bad Krozingen, Bad Krozingen, Baden-Württemberg, Germany
🇩🇪Universitäts-Klinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪Universitätsklinikum Mannheim, Mannheim, Baden-Württemberg, Germany
Overcoming High On-Treatment Platelet Reactivity (HPR) During Prasugrel Therapy With Ticagrelor
- First Posted Date
- 2013-06-05
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- LifeBridge Health
- Target Recruit Count
- 400
- Registration Number
- NCT01869309
- Locations
- 🇺🇸
Sinai Center for Thrombosis Research, Baltimore, Maryland, United States
Pharmacodynamic Effects of Prasugrel Compared With Ticagrelor in Patients With Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-06-10
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 110
- Registration Number
- NCT01852175
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
Cangrelor Prasugrel Transition Study
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- The Medicines Company
- Target Recruit Count
- 12
- Registration Number
- NCT01852019
- Locations
- 🇺🇸
Fletcher Allen Health Care, Burlington, Vermont, United States
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes
- Conditions
- Interventions
- First Posted Date
- 2013-05-13
- Last Posted Date
- 2016-10-17
- Lead Sponsor
- University of Florida
- Target Recruit Count
- 50
- Registration Number
- NCT01852214
- Locations
- 🇺🇸
University of Florida, Jacksonville, Florida, United States
A Study Exploring Two Strategies of Rivaroxaban (JNJ39039039; BAY-59-7939) and One of Oral Vitamin K Antagonist in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention
- First Posted Date
- 2013-04-12
- Last Posted Date
- 2017-09-19
- Lead Sponsor
- Janssen Scientific Affairs, LLC
- Target Recruit Count
- 2124
- Registration Number
- NCT01830543
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.